These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 3494841

  • 1. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
    Spearman ME, Goodwin RM, Apelgren LD, Bumol TF.
    J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
    [Abstract] [Full Text] [Related]

  • 2. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
    Spearman ME, Goodwin RM, Kau D.
    Drug Metab Dispos; 1987 May; 15(5):640-7. PubMed ID: 2891480
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
    Apelgren LD, Zimmerman DL, Briggs SL, Bumol TF.
    Cancer Res; 1990 Jun 15; 50(12):3540-4. PubMed ID: 2340502
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.
    Schneck D, Butler F, Dugan W, Littrell D, Petersen B, Bowsher R, DeLong A, Dorrbecker S.
    Clin Pharmacol Ther; 1990 Jan 15; 47(1):36-41. PubMed ID: 2295217
    [Abstract] [Full Text] [Related]

  • 6. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.
    Petersen BH, DeHerdt SV, Schneck DW, Bumol TF.
    Cancer Res; 1991 May 01; 51(9):2286-90. PubMed ID: 2015593
    [Abstract] [Full Text] [Related]

  • 7. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.
    Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, Strnad J, Rittmann-Grauer L, DeHerdt SV, Bumol TF.
    Cancer Res; 1990 Dec 01; 50(23):7634-40. PubMed ID: 1979247
    [Abstract] [Full Text] [Related]

  • 8. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
    Bumol TF, Baker AL, Andrews EL, DeHerdt SV, Briggs SL, Spearman ME, Apelgren LD.
    Targeted Diagn Ther; 1988 Dec 01; 1():55-79. PubMed ID: 2979063
    [No Abstract] [Full Text] [Related]

  • 9. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27.
    Schrappe M, Bumol TF, Apelgren LD, Briggs SL, Koppel GA, Markowitz DD, Mueller BM, Reisfeld RA.
    Cancer Res; 1992 Jul 15; 52(14):3838-44. PubMed ID: 1617657
    [Abstract] [Full Text] [Related]

  • 10. Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
    Apelgren LD, Bailey DL, Briggs SL, Barton RL, Guttman-Carlisle D, Koppel GA, Nichols CL, Scott WL, Lindstrom TD, Baker AL.
    Bioconjug Chem; 1993 Jul 15; 4(2):121-6. PubMed ID: 7873643
    [Abstract] [Full Text] [Related]

  • 11. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
    Starling JJ, Maciak RS, Law KL, Hinson NA, Briggs SL, Laguzza BC, Johnson DA.
    Cancer Res; 1991 Jun 01; 51(11):2965-72. PubMed ID: 2032233
    [Abstract] [Full Text] [Related]

  • 12. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
    Laguzza BC, Nichols CL, Briggs SL, Cullinan GJ, Johnson DA, Starling JJ, Baker AL, Bumol TF, Corvalan JR.
    J Med Chem; 1989 Mar 01; 32(3):548-55. PubMed ID: 2783975
    [Abstract] [Full Text] [Related]

  • 13. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ.
    Cancer Res; 1995 Jul 15; 55(14):3132-9. PubMed ID: 7606734
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding.
    Sung C, Youle RJ, Dedrick RL.
    Cancer Res; 1990 Nov 15; 50(22):7382-92. PubMed ID: 2224866
    [Abstract] [Full Text] [Related]

  • 15. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
    Stastny JJ, Das Gupta TK.
    Cancer Res; 1993 Dec 01; 53(23):5740-4. PubMed ID: 8242630
    [Abstract] [Full Text] [Related]

  • 16. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, Briggs SL, Starling JJ.
    Cancer Res; 1993 Sep 01; 53(17):3956-63. PubMed ID: 8358723
    [Abstract] [Full Text] [Related]

  • 17. Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A549-tumor-bearing nude mice.
    Jiang FN, Richter AM, Jain AK, Levy JG, Smits C.
    Biotechnol Ther; 1993 Sep 01; 4(1-2):43-61. PubMed ID: 8374512
    [Abstract] [Full Text] [Related]

  • 18. Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D.
    Johnson DA, Laguzza BC.
    Cancer Res; 1987 Jun 15; 47(12):3118-22. PubMed ID: 3495327
    [Abstract] [Full Text] [Related]

  • 19. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ.
    Bioconjug Chem; 2004 Jun 15; 15(6):1264-74. PubMed ID: 15546192
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
    Johnson DA, Baker AL, Laguzza BC, Fix DV, Gutowski MC.
    Cancer Res; 1990 Mar 15; 50(6):1790-4. PubMed ID: 2306731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.